Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants
Status:
RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This is a phase II double blind, placebo-controlled, randomized study of artesunate ointment for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)
Phase:
PHASE2
Details
Lead Sponsor:
Frantz Viral Therapeutics, LLC
Collaborators:
Anal Dysplasia Clinic MidWest Laser Surgery Care, LLC